$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

$pacb Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000129913024000183 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$39.97M
YoY Change		-28.23%
Cost Of Revenue		$29.96M
YoY Change		-20.71%
Gross Profit		$10.00M
YoY Change		-44.12%
Gross Profit Margin		25.03%
Selling, General & Admin		$43.75M
YoY Change		0.73%
% of Gross Profit		437.29%
Research & Development		$25.52M
YoY Change		-46.3%
% of Gross Profit		255.06%
Depreciation & Amortization		$11.05M
YoY Change		186.88%
% of Gross Profit		110.41%
Operating Expenses		$74.08M
YoY Change		-26.21%
Operating Profit		-$64.08M
YoY Change		-22.32%
Interest Expense		-$3.538M
YoY Change		-198.61%
% of Operating Profit
Other Income/Expense, Net		$6.890M
YoY Change		-18.99%
Pretax Income		-$60.73M
YoY Change		-21.72%
Income Tax		$0.00
% Of Pretax Income
Net Earnings		-$60.73M
YoY Change		-9.19%
Net Earnings / Revenue		-151.94%
Basic Earnings Per Share		-$0.22
Diluted Earnings Per Share		-$0.22
COMMON SHARES
Basic Shares Outstanding	273.9M shares	272.5M shares
Diluted Shares Outstanding		272.9M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$471.1M
YoY Change		-38.64%
Cash & Equivalents		$77.98M
Short-Term Investments		$393.2M
Other Short-Term Assets		$17.97M
YoY Change		13.72%
Inventory		$65.74M
Prepaid Expenses
Receivables		$29.38M
Other Receivables		$0.00
Total Short-Term Assets		$584.2M
YoY Change		-33.78%
LONG-TERM ASSETS
Property, Plant & Equipment		$31.95M
YoY Change		-20.79%
Goodwill		$369.1M
YoY Change		-20.43%
Intangibles		$436.4M
YoY Change		-5.5%
Long-Term Investments
YoY Change
Other Assets		$9.503M
YoY Change		-26.92%
Total Long-Term Assets		$865.8M
YoY Change		-14.79%
TOTAL ASSETS
Total Short-Term Assets		$584.2M
Total Long-Term Assets		$865.8M
Total Assets		$1.450B
YoY Change		-23.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$12.06M
YoY Change		-25.1%
Accrued Expenses		$19.18M
YoY Change		-44.65%
Deferred Revenue		$17.30M
YoY Change		-22.77%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$60.00M
YoY Change		-67.39%
LONG-TERM LIABILITIES
Long-Term Debt		$893.1M
YoY Change		0.13%
Other Long-Term Liabilities		$751.0K
YoY Change		-28.54%
Total Long-Term Liabilities		$751.0K
YoY Change		-28.54%
TOTAL LIABILITIES
Total Short-Term Liabilities		$60.00M
Total Long-Term Liabilities		$751.0K
Total Liabilities		$996.9M
YoY Change		-12.13%
SHAREHOLDERS EQUITY
Retained Earnings		-$2.151B
YoY Change		22.44%
Common Stock		$274.0K
YoY Change		6.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$453.1M
YoY Change
Total Liabilities & Shareholders Equity		$1.450B
YoY Change		-23.62%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$60.73M
YoY Change		-9.19%
Depreciation, Depletion And Amortization		$11.05M
YoY Change		186.88%
Cash From Operating Activities		-$45.46M
YoY Change		-30.25%
INVESTING ACTIVITIES
Capital Expenditures		-$787.0K
YoY Change		-194.82%
Acquisitions
YoY Change
Other Investing Activities		$22.28M
YoY Change		-90.84%
Cash From Investing Activities		$23.07M
YoY Change		-90.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		812.0K
YoY Change		-204.1%
NET CHANGE
Cash From Operating Activities		-45.46M
Cash From Investing Activities		23.07M
Cash From Financing Activities		812.0K
Net Change In Cash		-21.59M
YoY Change		-112.24%
FREE CASH FLOW
Cash From Operating Activities		-$45.46M
Capital Expenditures		-$787.0K
Free Cash Flow		-$44.68M
YoY Change		-32.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001299130
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Pacific Biosciences of California, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	16-1590339
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1305 O’Brien Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	521-8000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	PACB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	273863544	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77982000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179911000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	393165000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	451505000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29383000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	65737000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	56676000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17277000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17040000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	690000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	584234000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	742047000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31952000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32593000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1532000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2422000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	436426000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	456984000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15062000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19183000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45708000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	17292000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16342000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10675000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9591000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	783000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8326000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16933000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31606000	usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	893144000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	892243000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	751000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	751000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	996930000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1044709000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	274000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	268000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2602592000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2539892000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1553000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	219000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2151297000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1839075000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	453122000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	701304000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1450052000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1746013000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39967000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55691000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114790000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142164000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	3201000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	184000	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	7172000	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	550000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4562000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19691000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	763743000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17344000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	369061000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	462261000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9503000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13274000	usd
CY2024Q3	us-gaap	Assets Assets	1450052000	usd
CY2023Q4	us-gaap	Assets Assets	1746013000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	12064000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	267744000	shares
	us-gaap	Investment Income Net InvestmentIncomeNet	25000000.0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	401984000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2862000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4681000	usd
CY2024Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1414000	usd
CY2023Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	2825000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	4787000	usd
CY2024Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1610000	usd
CY2023Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1722000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	6202000	usd
CY2024Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3266000	usd
CY2023Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3965000	usd
CY2024Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3266000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	133376000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	123822000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	328311000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80204000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77982000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	385648000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2722000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36432000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	59997000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95029000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5455000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5530000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	20650000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	19550000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	273812000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	273812000	shares
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36615000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	267744000	shares
CY2024Q3	pacb	Loss On Purchase Commitment LossOnPurchaseCommitment	0	usd
CY2023Q3	pacb	Loss On Purchase Commitment LossOnPurchaseCommitment	0	usd
	pacb	Loss On Purchase Commitment LossOnPurchaseCommitment	998000	usd
	pacb	Loss On Purchase Commitment LossOnPurchaseCommitment	0	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	29963000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	37789000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	87566000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	98955000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	10004000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17902000	usd
	us-gaap	Gross Profit GrossProfit	27224000	usd
	us-gaap	Gross Profit GrossProfit	43209000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25516000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47514000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107456000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	142626000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	43746000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	43431000	usd
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	93200000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	8979000	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	8979000	usd
CY2024Q3	pacb	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	3649000	usd
CY2023Q3	pacb	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	741000	usd
	pacb	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	13377000	usd
	pacb	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	741000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1170000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-271000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1100000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	13960000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	74081000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	100394000	usd
	us-gaap	Operating Expenses OperatingExpenses	348509000	usd
	us-gaap	Operating Expenses OperatingExpenses	290128000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-64077000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-82492000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-321285000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-246919000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2033000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3538000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3588000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10655000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10772000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6890000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8505000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19718000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24301000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60725000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-77575000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-312222000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-235423000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10706000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10706000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-60725000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-66869000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-312222000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-224717000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2076000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	846000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1334000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2925000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58649000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66023000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-310888000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-221792000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	272915000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	255001000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	271631000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	249082000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	272915000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	255001000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	271631000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	249082000	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	492700000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-60725000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2076000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	812000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18259000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	453122000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	701304000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-312222000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1334000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7703000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	55003000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	453122000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	641999000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-66869000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	846000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	84761000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	76642000	usd
CY2023Q3	pacb	Stock Issued During Period Value Acquisitions Liquidity Bonus Plan StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan	2111000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	562904000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-224717000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2925000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	84761000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	76642000	usd
	pacb	Stock Issued During Period Value Acquisitions Liquidity Bonus Plan StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan	2111000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	189200000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14383000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	55534000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	763743000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-312222000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-224717000	usd
	us-gaap	Depreciation Depreciation	10932000	usd
	us-gaap	Depreciation Depreciation	8487000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20558000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1408000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	10912000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4940000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	55003000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	55534000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	93200000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0	usd
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	3395000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	10663000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	10088000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1100000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	13960000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2033000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	3715000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	4691000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-10706000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1002000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-667000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7232000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11700000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15394000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	22849000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3534000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7287000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2222000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1706000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-26665000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2055000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	875000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4867000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9252000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6396000	usd
	pacb	Increase Decrease In Business Combination Contingent Consideration Arrangements Contingent Consideration Liability IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability	0	usd
	pacb	Increase Decrease In Business Combination Contingent Consideration Arrangements Contingent Consideration Liability IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability	-732000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-7053000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1147000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-175408000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-201613000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4571000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6819000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	102000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	418164000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	553748000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	8061000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	595000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	480440000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	631253000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	65766000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71179000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	189200000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7703000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14383000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7325000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4368000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	490000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1397000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7213000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	190493000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-102429000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60059000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182633000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	388370000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2222000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80204000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	388370000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of September 30, 2024. Actual results could differ materially from these estimates.</span></div>
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	77982000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	179911000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	690000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1532000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2422000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	473369000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	634138000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20650000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19550000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	20650000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	19550000	usd
CY2024Q3	pacb	Business Combination Contingent Consideration Liability Measurement Period BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod	P5Y
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19550000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1100000	usd
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20650000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	469595000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1584000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	32000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	471147000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	690000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	690000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1532000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1532000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	631197000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	864000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	645000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	631416000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2422000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2422000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	321789000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	90655000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	412444000	usd
CY2024Q3	us-gaap	Investment Income Net InvestmentIncomeNet	6000000.0	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	19800000	usd
CY2023Q3	us-gaap	Investment Income Net InvestmentIncomeNet	9200000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	30697000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20168000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	18292000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	23436000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16748000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13072000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	65737000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	56676000	usd
CY2024Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	93200000	usd
CY2024Q2	pacb	Goodwill Impairment Discounted Cash Flow Model Discount Rate GoodwillImpairmentDiscountedCashFlowModelDiscountRate	0.120
CY2024Q2	pacb	Goodwill Impairment Increase In Basis Point Discount Rate GoodwillImpairmentIncreaseInBasisPointDiscountRate	0.0100
CY2024Q2	pacb	Additional Goodwill Impairment Change In Discount Rate AdditionalGoodwillImpairmentChangeInDiscountRate	85000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	462261000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	93200000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	369061000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	411539000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	30113000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	381426000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	411539000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9555000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	6853000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	27412000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	27412000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	27412000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	27412000	usd
CY2024Q3	pacb	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	264925000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	381426000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	22800000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	17300000	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5500000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5500000	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P5Y
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4800000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	10200000	usd
	pacb	Standard Product Warranty Period StandardProductWarrantyPeriod	P1Y
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3462000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1651000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	5675000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3361000	usd
CY2023Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3965000	usd
CY2024Q3	pacb	Restructuring Charges Worker Adjustment And Retraining Notification Warn Act And Other Employee Benefits RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits	5500000	usd
CY2024Q3	us-gaap	Severance Costs1 SeveranceCosts1	4500000	usd
	us-gaap	Restructuring Charges RestructuringCharges	12372000	usd
	us-gaap	Payments For Restructuring PaymentsForRestructuring	12057000	usd
CY2024Q3	us-gaap	Restructuring Reserve RestructuringReserve	315000	usd
CY2024Q3	us-gaap	Restructuring And Related Cost Expected Cost Remaining1 RestructuringAndRelatedCostExpectedCostRemaining1	2074000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	COMMITMENTS AND CONTINGENCIES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements, primarily relating to our corporate offices. See </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8 – Commitments and Contingencies</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled “Leases”, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2023 for information regarding the Company’s maturity of lease liabilities under its lease agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibf032b7334cc4cbbac77d92b0e9c5a6d_103" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings, in Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of September 30, 2024 and December 31, 2023.</span></div>
CY2023Q4	pacb	Additional Liability Associated With Indemnification Obligations AdditionalLiabilityAssociatedWithIndemnificationObligations	0	usd
CY2024Q3	pacb	Additional Liability Associated With Indemnification Obligations AdditionalLiabilityAssociatedWithIndemnificationObligations	0	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18259000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19691000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55003000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55534000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-60725000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-66869000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-312222000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-224717000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	272915000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	255001000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	271631000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	249082000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	272915000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	255001000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	271631000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	249082000	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39967000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55691000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114790000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142164000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39967000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55691000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114790000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142164000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
pacb-20240930_cal.xml	Edgar Link	unprocessable
0001299130-24-000183-index-headers.html	Edgar Link	pending
0001299130-24-000183-index.html	Edgar Link	pending
0001299130-24-000183.txt	Edgar Link	pending
0001299130-24-000183-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pacb-10qxexx311xq3x24.htm	Edgar Link	pending
pacb-10qxexx312xq3x24.htm	Edgar Link	pending
pacb-10qxexx321xq3x24.htm	Edgar Link	pending
pacb-10qxexx322xq3x24.htm	Edgar Link	pending
pacb-20240930.htm	Edgar Link	pending
pacb-20240930.xsd	Edgar Link	pending
pacb-20240930_g1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
pacb-20240930_def.xml	Edgar Link	unprocessable
pacb-20240930_htm.xml	Edgar Link	completed
pacb-20240930_lab.xml	Edgar Link	unprocessable
pacb-20240930_pre.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

2024 Q4 Form 10-Q Financial Statement

#000129913024000183 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

2024 Q4 Form 10-Q Financial Statement

#000129913024000183 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb